Acetylsalicylic Acid Exhibits Antitumor Effects in Esophageal Adenocarcinoma Cells In Vitro and In Vivo

Abstract

Although these results need to be confirmed in other EAC cells, our data suggest a role for ASA in the treatment of this tumor.

Aspirin acts in esophageal cancer: a brief review

“…The experiments in vitro and in vivo are made to evaluate the effect of aspirin in esophageal adenocarcinoma cells, which found decreasing levels of PGE-2 both intracellularly and in cell culture supernatants and supports the correlation of COX-2 dependent mechanisms and the antitumor effects of aspirin (31).…”

“…In vivo, the progression of the esophageal cancer was lower in aspirin use mice than the non-aspirin use group. Maximum tumor inhibition in this study was 92% (low-dose group) and 85% (high-dose group), respectively (31).…”

“…The risk of developing into esophageal adenocarcinoma in Barrett's esophagus patients was 11.3 times higher than general population (95% CI, 8.8-14.4) (30). Although it is reported effective of aspirin in reducing the incidence of Barrett's esophagusderived esophageal adenocarcinoma (31), epidemiological evidences of aspirin on the risk of Barrett's esophagus remain inadequate to reach a definitive conclusion (32). Another nested case-control study failed to demonstrate the association between aspirin or non-aspirin NSAIDs and esophageal cancer (33).…”

Effects of chronic low‐dose aspirin treatment on tumor prevention in three mouse models of intestinal tumorigenesis

“…Moreover, aspirin administration via drinking water has been used in other murine disease models before. [43][44][45][46] Our results suggest that low-dose aspirin represents an effective tumor-preventive agent in the context of inflammation-associated colon tumorigenesis. In the AOM model for sporadic colon tumor development, the aspirin-induced reduction in tumor incidence was still significant, but with a less marked effect, while in the APC Min/+ model aspirin treatment failed to show significant tumor-preventive efficacy.…”

“…Administration in the drinking water makes assessment of exact dose difficult per mouse, however, we tried to control for this by (a) comparing the COX‐1 inhibitory effect of the drinking water administration with gavaging at a dose of 25 mg/kg in initial pharmacodynamic dosing experiments (Figure ; Table ); and (b) by regular control of the consumed drinking water volume that mice achieved a similar dose. Moreover, aspirin administration via drinking water has been used in other murine disease models before …”